The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of placebo and semaglutide therapy in 74 KTR at risk of post-transplant diabetes mellitus (PTDM).

Start Date05 Jan 2026

Sponsor / Collaborator

University Health Network

NCT06934655

/ Not yet recruitingPhase 3IIT

Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth

This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial will involve 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery. Participants will be randomized to either (1) semaglutide 2.4 mg weekly or (2) standard care for 24 months. Primary, secondary, and tertiary outcomes will be assessed at multiple time points: 1-month, day of surgery, and 1-, 3-, 6-, 9-, 12-, 18-, and 24-months postoperatively. We hypothesize that early re-initiation of semaglutide will be safe, well-tolerated, and lead to greater improvements in obesity, cardiometabolic risk, and eating behaviors.

Start Date01 Nov 2025

Sponsor / Collaborator

Children's Hospital Los Angeles

NCT06909006

/ Not yet recruitingPhase 3IIT

Obesity and Semaglutide in Type 1 Diabetes Therapy: a Multicentre, Randomised, Double-Blinded, Placebo-Controlled, Investigator-Initiated Trial

The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic ketoacidosis for patients with established Type 1 Diabetes.

Start Date01 Oct 2025

Sponsor / Collaborator

Zealand University Hospital

[+1]

100 Clinical Results associated with Semaglutide (Novo Nordisk)

100 Translational Medicine associated with Semaglutide (Novo Nordisk)

100 Patents (Medical) associated with Semaglutide (Novo Nordisk)

324

Literatures (Medical) associated with Semaglutide (Novo Nordisk)

01 Jul 2025·Current Neuropharmacology

In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicidal Ideation and Substance Use Disorder

Article

Author: Pollack, Aryeh R ; Badgaiyan, Rajendra D ; Ashford, J Wes ; Khalsa, Jag H ; Blum, Kenneth ; Baron, David ; Bowirrat, Abdalla ; Schmidt, Sergio ; Gardner, Eliot L ; Elman, Igor ; Carney, Paul R ; Hanna, Colin ; Lewandrowski, Kai-Uwe ; Fuehrlein, Brian ; Sharafshah, Alireza ; Wang, Gene Jack ; Gold, Mark S ; Dennen, Catherine A ; Pinhasov, Albert ; Braverman, Eric R ; Cadet, Jean Lud ; Modestino, Edward J ; Fiorelli, Rossano Kepler Alvim ; Cortese, Rene ; Thanos, Panayotis K

Introduction::

Glucagon-Like Peptide-1 Receptor (GLP1R) agonists have become widespread anti-obesity/diabetes pharmaceuticals in the United States.

Aim::

This article aimed to provide our current knowledge on the plausible mechanisms linked to the role of Ozempic (Semaglutide), which is generalized as one of the anti-addiction compounds.

Methods::

The effects of GLP1R agonists in Alcohol Use Disorder (AUD) and substance use disorder (SUD) are mediated, in part, through the downregulation of dopamine signaling. We posit that while GLP1R agonism could offer therapeutic advantages in hyperdopaminergia, it may be detrimental in patients with hypodopaminergia, potentially leading to long-term induction of Suicidal Ideation (SI). The alleged posit of GLP1 agonists to induce dopamine homeostasis is incorrect. This study refined 31 genes based on the targets of Ozempic, GLP1R, and related enzymes for SI and 10 genes of the Genetic Addiction Risk Score (GARS) test. STRING-MODEL refined 29 genes, and further primary analyses indicated associations of GLP1R with DRD3, BDNF, CREB1, CRH, IL6, and DPP4.

Results::

In-depth silico enrichment analysis revealed an association between candidate genes and depressive phenotypes linked with dopaminergic signaling. Finally, through primary and in-depth silico analyses, we demonstrated multiple findings supporting that GLP1R agonists can induce depression phenotypes.

Conclusion::

Our findings suggest that associated polymorphisms seem to have overlapping effects with addictive behaviors of Reward Deficiency Syndrome (RDS) and dopamine regulation. Consequently, GLP1R agonists may represent a double-edged sword, potentially triggering both antiaddictive effects and SI by exacerbating depressive phenotypes. Thus, we encourage the scientific community to perform further empirical clinical studies to confirm this proposed pathway. Keywords: GLP1, Ozempic, suicide ideation, substance use disorder, dopamine homeostasis, in-depth in silico.

01 May 2025·LANCET

Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial

Article

Author: Rasouli, Neda ; Catarig, Andrei-Mircea ; Bonaca, Marc P ; Verma, Subodh ; Houlind, Kim ; Ramesh, Chethana Kalmady ; Videmark, Alex ; Ludvik, Bernhard ; Nordanstig, Joakim ; Sourij, Harald

BACKGROUND:

Peripheral artery disease is a highly morbid type of atherosclerotic vascular disease involving the legs and is estimated to affect over 230 million individuals globally. Few therapies improve functional capacity and health-related quality of life in people with lower limb peripheral artery disease. We aimed to evaluate whether semaglutide improves function as measured by walking ability as well as symptoms, quality of life, and outcomes in people with peripheral artery disease and type 2 diabetes.

METHODS:

STRIDE was a double-blind, randomised, placebo-controlled trial done at 112 outpatient clinical trial sites in 20 countries in North America, Asia, and Europe. Participants were aged 18 years and older, with type 2 diabetes and peripheral artery disease with intermittent claudication (Fontaine stage IIa, able to walk >200 m) and an ankle-brachial index of less than or equal to 0·90 or toe-brachial index of less than or equal to 0·70. Participants were randomly assigned (1:1) using an interactive web response system to receive subcutaneous semaglutide 1·0 mg once per week for 52 weeks or placebo. The primary endpoint was the ratio to baseline of the maximum walking distance at week 52 measured on a constant load treadmill in the full analysis set. Safety was evaluated in the safety analysis set. This trial is registered with ClinicalTrials.gov, NCT04560998 and is now completed.

FINDINGS:

From Oct 1, 2020, to July 12, 2024, 1363 patients were screened for eligibility, of whom 792 were randomly assigned to semaglutide (n=396) or placebo (n=396). 195 (25%) participants were female and 597 (75%) were male. Median age was 68·0 years (IQR 61·0-73·0). The estimated median ratio to baseline in maximum walking distance at week 52 was significantly greater in the semaglutide group than the placebo group (1·21 [IQR 0·95-1·55] vs 1·08 [0·86-1·36]; estimated treatment ratio 1·13 [95% CI 1·06-1·21]; p=0·0004). Six serious adverse events in five (1%) participants in the semaglutide group and nine serious adverse events in six (2%) participants in the placebo group were possibly or probably treatment related, with the most frequent being serious gastrointestinal events (two events reports by two [1%] in the semaglutide group and five events reported by three [1%] in the placebo group). There were no treatment-related deaths.

INTERPRETATION:

Semaglutide increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes. Research implications include the need for future studies to further elucidate mechanisms of benefit and to assess the efficacy and safety in patients with peripheral artery disease who do not have type 2 diabetes.

FUNDING:

Novo Nordisk.

01 May 2025·Diabetes Therapy

PIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes

Article

Author: Deinega, Alisa ; Giordano, Carla ; Desenzani, Paolo ; Memoli, Pasqualina ; Faldetta, Maria Cassone ; Gioia, Daniela ; Ventura, Claudio ; Serra, Rosalia ; Gallo, Marco ; Berra, Cesare ; Braae, Uffe Christian ; Memoli, Giuseppe ; Manetti, Francesco ; Bisio, Alessandro ; Paccagnella, Agostino ; Strazzabosco, Marco ; Mirani, Marco ; Marangoni, Alberto ; Anzaldi, Massimiliano ; De Cata, Pasquale ; Girelli, Angela ; Di Loreto, Chiara ; De Cosmo, Salvatore ; Scatena, Alessia ; Manti, Roberta ; Ferrara, Lidia

INTRODUCTION:

The PIONEER REAL Italy study examined the clinical outcomes associated with oral semaglutide in real-world settings.

METHODS:

This was a multicenter, prospective, non-interventional, single-arm study in adults with type 2 diabetes (T2D) who were treatment-naive to injectable glucose-lowering medications. Participants initiated oral semaglutide at doses of 3, 7, or 14 mg, and were followed for 34-44 weeks. The primary endpoint was the change in glycated hemoglobin (HbA_1c) from baseline to the end of study (EoS). Secondary endpoints were the change in body weight (BW), the percentage of participants attaining HbA_1c < 7%, composite endpoints of HbA_1c reduction ≥ 1%-point plus BW reduction (≥ 3%/ ≥ 5%), and treatment satisfaction measured using Diabetes Treatment Satisfaction Questionnaires (DTSQ) status. Safety was assessed in participants who received ≥ 1 dose of oral semaglutide.

RESULTS:

Of 445 eligible participants, 398 completed the study; 351 (78.9%) remained on oral semaglutide at EoS. The median time of treatment follow-up was 40 weeks for each participant. At baseline, participants had a mean (standard deviation [SD]) age of 62.9 (10.2) years, HbA_1c of 7.8% (1.3), T2D duration of 8.0 (6.9) years, and BW of 87.8 (19.0) kg. The estimated changes (95% confidence interval) from baseline to EoS in HbA_1c and BW were - 0.9%-points (- 1.01 to - 0.82; p < 0.0001) and - 3.8 kg (- 4.45 to - 3.24; p < 0.0001), respectively. At EoS, 65.1% achieved HbA_1c < 7%; 25.5% and 19.1% reached HbA_1c reduction ≥ 1%-point plus ≥ 3% and ≥ 5% reduction in BW, respectively. DTSQ status improved significantly at EoS (estimated change + 5.24; 95% CI, 5.24 to 6.61, p < 0.0001). Of participants who remained on oral semaglutide at EoS, 72.6% received a 7-mg dose. No new safety signals were observed.

CONCLUSIONS:

In Italy, the real-world clinical outcomes associated with oral semaglutide in adults with T2D complemented the findings from clinical trials. This reassures oral semaglutide usage in routine clinical practice.

TRIAL REGISTRATION:

NCT05230615.

2,042

News (Medical) associated with Semaglutide (Novo Nordisk)

16 May 2025

·www.prnewswire.com

Weekly Recap: 14 Health Press Releases You Need to See

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including the 2025-2026 Best OTC Medicine & Health Products, Lilly's collaboration expansion with Purdue University, and a breakthrough in gene editing. NEW YORK, May 16, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Continue Reading PR Newswire Weekly Health Press Release Roundup, May 12-16, 2025. World's First Patient Treated with Personalized CRISPR Gene Editing Therapy at Children's Hospital of Philadelphia "We want each and every patient to have the potential to experience the same results we saw in this first patient, and we hope that other academic investigators will replicate this method for many rare diseases and give many patients a fair shot at living a healthy life," said Kiran Musunuru, MD, PhD, the Barry J. Gertz Professor for Translational Research in Penn's Perelman School of Medicine. $101M XPRIZE Healthspan Awards First Milestone Winners Driving Toward Revolutionary Healthy Aging Advances Launched in November 2023, the $101M XPRIZE Healthspan is the first health-focused competition of its kind, incentivizing teams to develop proactive, accessible therapeutic solutions that restore muscle, cognition, and immune function by a minimum of 10 years, with a goal of 20 years, in persons aged 50-80 years, in one year or less. U.S. News Announces the 2025-2026 Best OTC Medicine & Health Products The brands with the most No. 1 products among the 2025-2026 rankings are Nature Made (7), followed by CeraVe (6) and Neutrogena (5); the companies with the most No. 1 products are Haleon plc, followed by Kenvue Inc., Prestige Consumer Healthcare Inc., The Procter & Gamble Company and L'Oreal Usa, Inc. FDA Approves Teal Health's Teal Wand™--The First and Only At-Home Self-Collection Device for Cervical Cancer Screening, Introducing a Comfortable Alternative to In-Person Screening Women can now collect their own sample from the privacy of home, no speculum required, and mail it to a certified lab to be tested on the same test as the doctor's office, with the same accuracy. Pager Health and Protera Health Team Up to Expand Access to Value-Based, Virtual-First MSK Care Pager Health's omnichannel care navigation solution will rapidly identify members with potential MSK-related issues and connect them seamlessly to Protera Health's virtual MSK program. From there, members will be directed to in-home care, in-network physical therapy or orthopedic surgical consults as appropriate. Sanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing "Sanofi's 13,000 US-based employees are pioneering the research and development of first- and best-in-class medicines across numerous therapeutic areas. Our expected investments in the US will be substantial and will help ensure the production of key medicines in the US," said Paul Hudson, Sanofi Chief Executive Officer. In new SELECT trial analysis, early reduction in cardiovascular events was observed with Wegovy®, before clinically meaningful changes in body weight "For people with obesity and existing cardiovascular disease, preventing another heart attack or stroke is vitally important. Seeing this SELECT secondary data demonstrate that patients experienced MACE risk reduction within three months is remarkable," said Dr. Jason Brett, MD, Principal Medical Head at Novo Nordisk Inc. Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation The Lilly-Purdue 360 Initiative aims to achieve several key goals, including discovering and accelerating the delivery of medicines to patients; bridging the gap between laboratory discoveries and clinical applications; creating more resilient, efficient and sustainable supply chains; and deploying innovative, scalable approaches to workforce development. Guardian adds over 20 new and innovative benefits to its hospital indemnity insurance policy, designed to inspire well-being® Guardian's enhanced hospital indemnity insurance policy becomes one of the industry's most comprehensive offerings, going further to support workers' mental, physical, and financial well-being needs. As part of these additions, Guardian becomes the first carrier to include fertility health, family-building, and caregiving wellness solutions directly in hospital indemnity insurance. U.S. Drug Spending Up 10.2% in 2024, with Weight Loss Drugs Remaining Top Driver Clinic drug spending rose sharply — up 14.4% to $158.2 billion — while nonfederal hospitals saw a more modest 4.9% increase to $39.0 billion. With GLP-1 shortages largely resolved, continued growth in this category is expected, though direct-to-consumer channels may complicate efforts to track usage trends. American College of Lifestyle Medicine Announces Integration of First Set of Lifestyle Behavior Assessment Tools Into Epic Electronic Health Records The new tools include ACLM's lifestyle medicine short form assessment tool, a clinical survey to capture patient lifestyle behaviors and readiness for change; ACLM's Diet Screener, which helps clinicians quickly capture a picture of a patient's diet during routine medical appointments; the Physical Activity Vital Sign (PAVS) tool for assessing physical activity in adults; as well as additional tools to capture lifestyle behaviors and opportunities for change. Hearing Wellness Pioneer Eargo Launches Eargo 8 As Its Newest Flagship Hearing Aid Eargo 8 was thoughtfully engineered with premium features, technology, and design while delivering essential post-purchase assistance for a seamless integration into users' lives. Eargo 8 is FDA cleared and its MSRP is $2,699. AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas The strategic collaboration will leverage ADARx's RNA discovery expertise and proprietary siRNA technology, which has the potential to enable sustained and precise mRNA silencing. AbbVie will contribute its expertise in antibody engineering, antibody drug conjugates (ADCs) and tissue delivery approaches as appropriate, to augment ADARx's discovery efforts. MavriX Bio Announces FDA Clearance of IND Application to Initiate First-in-Human Study of Gene Therapy for Angelman Syndrome "We are thrilled to achieve this critical milestone and move one step closer to delivering the first gene therapy to individuals living with Angelman syndrome," said Allyson Berent, DVM, DACVIM, Chief Development Officer of MavriX Bio. "The clearance of our IND signals a key transition point for our development program and our unwavering commitment to advance novel therapeutic options and a potential single treatment therapy for the Angelman community." For more news like this, check out all of the latest health-related releases from PR Newswire. Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most. Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers, and freelancers have access to the following free features: Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story. Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles. Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more. About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at [email protected]. SOURCE PR Newswire WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

License out/in

15 May 2025

·www.echemi.com

Ozempic Weight Loss Injections Could Slash Cancer Risk by 41 Percent

On May 12, 2025, researchers revealed that Ozempic and other GLP-1 receptor agonists may reduce the risk of cancers linked to obesity by up to 41%, offering benefits beyond weight loss. Excess weight is the second leading cause of cancer in the UK, responsible for over 1 in 20 cases. A study examined individuals with obesity and type 2 diabetes who had no prior cancer diagnosis and were treated with GLP-1 receptor agonists. Over a follow-up period of 7.5 years, these drugs lowered the risk of cancers such as breast, bowel, pancreatic, and gallbladder cancer. Experts suggest the anti-cancer effects may come from reduced inflammation and improved natural killer cell function, which helps the body destroy cancer cells. The findings highlight that these drugs provide metabolic and immune benefits that go beyond controlling appetite. This breakthrough signals a new frontier in cancer prevention, but researchers stress the need for further studies to fully understand how these medications can be used in preventing and treating cancer.

14 May 2025

·firstwordpharma.com

Novo bets on Septerna's GPCR expertise in pursuit of oral obesity, diabetes drugs

Novo Nordisk is hoping to use Septerna's GPCR drug discovery expertise in its quest to develop oral small-molecule drugs for obesity, type 2 diabetes and other cardiometabolic diseases. The deal, announced Wednesday, is potentially worth about $2.2 billion and includes upfront and near-term milestone payments of over $200 million.The companies will start work on four initial development programmes directed to one or more GPCR targets, including GLP-1, GIP and glucagon receptors. The parties will utilise Septerna's Native Complex Platform, which is designed to target specific GPCRs and uncover novel binding pockets for validated receptors, whilst pursuing a wide spectrum of pharmacologies, including agonists, antagonists and allosteric modulators.Novo's pipeline already features a number of oral drugs for cardiometabolic diseases, including a long-acting co-agonist of GLP-1 and amylin, as well as an oral version of its GLP-1 semaglutide, currently under review at the FDA. Already this year, the Danish drugmaker has inked obesity-focused deals with Lexicon Pharmaceuticals — for an oral small-molecule inhibitor of ACSL5 — and The United Laboratories — for certain rights to a long-acting triple agonist of the GLP-1, GIP and glucagon receptors. Marcus Schindler, Novo's chief scientific officer, explained that "leveraging different modalities creates important optionality in our pipeline in terms of potential targets, dosing regimens and scalability."The companies will jointly conduct research activities from discovery through development candidate selection, with Novo subsequently having sole responsibility for all global development and commercialisation activities. Additionally, Novo will cover all R&D expenses for partnered programmes, with Septerna eligible for subsequent R&D and commercial milestones, as well as tiered sales royalties.Meanwhile, Septerna has the right to opt in to a worldwide profit share for one programme in the collaboration in lieu of future milestones and sales royalties.

License out/in

100 Deals associated with Semaglutide (Novo Nordisk)

External Link

KEGG	Wiki	ATC	Drug Bank
D10025	Semaglutide (Novo Nordisk)	A10BJ06	DB13928

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Chronic Kidney Diseases	United States	Novo Nordisk A/S	28 Jan 2025
Chronic Kidney Diseases	United States	Novo Nordisk, Inc.	28 Jan 2025
Stroke	Australia	Novo Nordisk Pharmaceuticals Pty Ltd.	16 Dec 2024
Myocardial Infarction	Canada	Novo Nordisk Canada, Inc.	27 Nov 2024
Obesity	United States	Novo Nordisk, Inc.	04 Jun 2021
Overweight	United States	Novo Nordisk, Inc.	04 Jun 2021
Diabetes Mellitus, Type 2	United States	Novo Nordisk, Inc.	05 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nonalcoholic Steatohepatitis	NDA/BLA	United States	Novo Nordisk A/S	30 Apr 2025
Albuminuria	Phase 3	Canada	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Germany	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Netherlands	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Spain	Novo Nordisk A/S	14 Mar 2022
Osteoarthritis, Knee	Phase 3	United States	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Canada	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Colombia	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Denmark	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	France	Novo Nordisk A/S	01 Oct 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05786521 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Insulin Resistance \| Prediabetic State ... View more	20	Semaglutide Injectable Product+Lifestyle Counseling (Semaglutide and Lifestyle Intervention)	efrumhvtpk(avqjblhqrp) = lpnyeocnem frwfppthhy (qswsstdlut, zjrioxyqwm - ocdywydwrw) View more	-	04 May 2025
				Lifestyle Counseling (Lifestyle Intervention)	efrumhvtpk(avqjblhqrp) = givaxqsptd frwfppthhy (qswsstdlut, gyscbsiyef - itidgejrzz) View more
NCT04822181 (ESSENCE, PRNewswire \| Pubmed) Manual	Phase 3	Nonalcoholic Steatohepatitis	800	Semaglutide 2.4 mg	udxmeycpkm(smdapukmsr) = pnbernbgcm zxbrhgmuqv (uurqjhgpcu ) View more	Positive	30 Apr 2025
				Placebo	udxmeycpkm(smdapukmsr) = dvfmqzbaaj zxbrhgmuqv (uurqjhgpcu ) View more
NCT03574597 (SELECT, PRNewswire) Manual	Phase 3	Overweight \| Obesity	17,604	司美格鲁肽2.4mg	zuqnfmdujy(assaskfqbj) = iowofzxmsg eojlvdrqcn (ldifnlfdgi ) View more	Positive	03 Apr 2025
				Placebo	-
NCT04998136 (CTgov)	Phase 3	Obesity	150	Placebo (semaglutide 2.4 mg)	xxdvhuvmls(dlzmnhtwyp) = hewfhiqkjl clblikcpzw (gqedixwgrh, 5.8) View more	-	03 Apr 2025
NCT03914326 (SOUL, Pubmed \| N Engl J Med) Manual	Phase 3	Diabetes Mellitus, Type 2	9,650	Oral Semaglutide	urymbpdnwh(hkdzuxxyml) = tehvugezwg hxwxtsdhxb (mbpvawpqic ) View more	Positive	29 Mar 2025
				Placebo	urymbpdnwh(hkdzuxxyml) = jycwvhlqbm hxwxtsdhxb (mbpvawpqic ) View more
NCT05230615 (PIONEER REAL Italy, Pubmed \| Diabetes Ther)	Not Applicable	Diabetes Mellitus, Type 2	445	Oral Semaglutide 3 mg	hykzixdvod(wsfbszdsjq) = pjttfpyoka yirfbndeth (uktpsiufts )	Positive	25 Mar 2025
				Oral Semaglutide 7 mg	hykzixdvod(wsfbszdsjq) = tfqxkenbwc yirfbndeth (uktpsiufts )
NCT05520775 (CTgov)	Phase 2	Alcohol Use Disorder \| Smoking	48	Semaglutide (Semaglutide)	fsnyoookgc(aszyxoigxt) = hxwczwykkv rehplpheks (xyujvxwily, 27.98) View more	-	25 Mar 2025
				Sham/placebo (Sham/Placebo)	fsnyoookgc(aszyxoigxt) = yorhxvlkyq rehplpheks (xyujvxwily, 24.49) View more
NCT03819153 (FLOW, CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Chronic Kidney Diseases	3,533	semaglutide (Semaglutide)	zvlxizssxo = diixhdpnfl xruytqxfup (ewwuwuoduj, pgqagrzjct - ocargnpzif) View more	-	20 Mar 2025
				Placebo (semaglutide) (Placebo)	zvlxizssxo = waaqxvgeyd xruytqxfup (ewwuwuoduj, ntceornwow - oqhigogqso) View more
Drugs Manual	Not Applicable	Obesity	364	Semaglutide	ucfzqrikod(qmtjlmgqsa) = tkqjconunm yvdrmpyzhh (fgmwjbyjyd )	Negative	12 Mar 2025
				Control (No Semaglutide)	ucfzqrikod(qmtjlmgqsa) = hiwdyvtigi yvdrmpyzhh (fgmwjbyjyd )
NCT04560998 (STRIDE, Pubmed \| Lancet) Manual	Phase 3	Diabetes Mellitus, Type 2 \| Peripheral Arterial Disease	792	Semaglutide	tglwcldmdy(huyvbksjnv) = iqcfhsqrtw lupphbwhgh (noasdqaifu, 0.95 - 1.55) View more	Positive	01 Mar 2025
				Placebo	tglwcldmdy(huyvbksjnv) = jewfsxixph lupphbwhgh (noasdqaifu, 0.86 - 1.36) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis